Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Injectable PrEP Clear all
Recruiting No phase listed Observational

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Timeline
2026 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Not listed Not applicable Interventional

The Cheeky Study: A Novel Delivery System for CAB-RPV LA

NCT05979714
View directory record Official record
Conditions
HIV Infections
Interventions
Patient-centered injection site, Patient-centered adherence support, Provider education, Improved clinic communication strategies
Other · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

NCT06501781
View directory record Official record
Conditions
HIV Infections, Substance Use
Interventions
Peer Activate-LAI, Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
View directory record Official record
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed No phase listed Observational

The Presence and Role of Zygomatic-temporal Neuroma Triggering Cluster Headache

NCT04845451
View directory record Official record
Conditions
Cluster Headache, Craniofacial Pain Syndrome
Interventions
Minimal surgical exploration for a neuroma
Other
Lead sponsor
FARO T. OWIESY, M.D
Other
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing PrEP Uptake and Adherence Among Male Sex Workers

NCT05736614
View directory record Official record
Conditions
Prevention
Interventions
Stage 1 Strength Based Case Management (SBCM) Condition, Stage 2 PrEPare for Work Intervention Condition
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

NCT01087489
View directory record Official record
Conditions
Pain
Interventions
4% lidocaine, 3.5% ophthalmic lidocaine gel
Drug
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

NCT07218211
View directory record Official record
Conditions
HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use
Interventions
Lenacapavir long-acting
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Information Seeking About Pre-exposure Prophylaxis

NCT05728034
View directory record Official record
Conditions
Pre-exposure Prophylaxis
Interventions
Injectable PrEP information, Oral PrEP information
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 34 Years · Male only
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Not yet recruiting No phase listed Observational

Long-Acting Injectable HIV PrEP PROs

NCT07379658
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis
Interventions
Interview and survey to evaluate patient reported outcomes between the two medications.
Other
Lead sponsor
Anupama Raghuram MD
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

NCT04760691
View directory record Official record
Conditions
HIV, Prophylaxis, Transgender
Interventions
Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

PrEP Intervention for People Who Inject Substances and Use Methamphetamine

NCT04523519
View directory record Official record
Conditions
HIV Infections
Interventions
Video directly observed therapy with contingency management, Integrated Next-Step Counseling
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years · Male only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study

NCT07462611
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, PrEP
Interventions
PrEP Uptake with Rapid Start, Pre-Exposure Prophylaxis (PrEP) Persistence
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence

NCT07335289
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis Use
Interventions
Choice of follow up, Follow up via standard clinic
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Not listed Phase 4 Interventional

IO vs IV Vancomycin in Tourniquetless TKA

NCT05705843
View directory record Official record
Conditions
Infection, Surgical Site
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 6, 2026, 10:12 AM EDT
Active, not recruiting Phase 4 Interventional Results available

IO Vancomycin in TSA

NCT05831774
View directory record Official record
Conditions
Shoulder Injuries
Interventions
Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 6, 2026, 10:12 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 6, 2026, 10:12 AM EDT
Recruiting No phase listed Observational

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

NCT04979728
View directory record Official record
Conditions
HIV Treatment, HIV Prevention
Interventions
At Home Self-Collections
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 6, 2026, 10:12 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofacial Pain
Interventions
Trigger point injection with 1% lidocaine, Lidocaine patch 5%
Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 6, 2026, 10:12 AM EDT